Photo of Daniel W. Rosenberg, Ph.D.

Daniel W. Rosenberg, Ph.D.

Professor of Medicine and Health Net Inc., Chair in Cancer Biology
Investigator, Center for Molecular Oncology
Director, Colon Cancer Prevention Program, Carole and Ray Neag Comprehensive Cancer Center
Department of Medicine (primary); Department of Genetics and Developmental Biology (secondary); Department of Molecular and Cell Biology - Storrs Campus (adjunct faculty)
Academic Office Location:
Academic Research Building, E1056
UConn Health
263 Farmington Avenue
Farmington, CT 06030-3101
Phone: 860-679-8704
Fax: 860-679-7639

Center for Molecular Oncology

Cell Biology Graduate Program

Genetics and Developmental Biology Graduate Program

Curriculum Vitae:

I was initially trained as an Environmental Toxicologist. My research interests gradually evolved into the field of GI cancer - its causes, treatments and prevention. After spending 7 years at the Rockefeller University in New York City as a graduate fellow and postdoctoral fellow in the laboratory of Drs. Attallah Kappas and George Drummond, I decided to work as a Toxicologist at the Chevron Environmental Health Center in Northern California for two years. This experience gave me insight into how one can apply their academic training in the corporate setting. After two years in industry, I decided to return to the Rockefeller University as an Assistant Professor. During this time I developed a keen interest in the field of cancer biolgy, eventually joining the faculty at the University of Connecticut in Storrs where I became a tenured faculty member in 1996. In 2000, I joined the Center for Molecular Oncology at the UConn Health Center, where I have worked ever since. During this time, I created a Colon Cancer Prevention Program and and established a laboratory that is focused primarily on understanding early neoplasia. Our work uses a number of complex genetic models to study colon cancer, including a number of different transgenic mouse models. We have been continuously funded by the NIH for over 25 years and currently have over $6M in extramural research funding. Our current studies span a wide spectrum, from clinical investigations to basic molecular mechanisms (including stem cell dynamics) to developing novel therapeutic and preventive strategies for GI diseases, including cancer and inflammation. We currently have ongoing collaborations with scientists at the Jackson Laboratory for Genomic Medicine, Fluidigm Corporation and Thetis Pharmaceuticals. Our work is currently funded by the NIH/NCI, American Institute for Cancer Research, California Walnut Commission, Thetis Pharmaceuticals, Fluidigm Corporation, Cumberland Pharmaceuticals and the Peanut Commission.

B.S.SUNY BuffaloBiochemistry
M.S.University of MichiganToxicology/Environmental Health Sciences
Ph.D.University of MichiganToxicology/Environmental Health Sciences

Post-Graduate Training
FellowshipThe Rockefeller UniversityGuest Investigator
PostdoctoralThe Rockefeller UniversityPostdoctoral Fellow in Pharmacology
Professional TrainingChevron Environmental Health CenterStudy Director in Toxicology

Name of Award/HonorAwarding Organization
2017 CICATS M1 Mentorship Award
External Advisory Committee of the Marshall University COBRE Program -- Member
HealthNet Inc., Chair in Cancer BiologyUConn Health Center
Connecticut Academy of Science and Engineering (CASE) Elected Member
Editor, Special Issue of Mutation Research, "Application of Genomic Technologies to the Study of Colon Cancer" NIH chemoprevention Study Section, Full member
Visiting Professor, NCCRI, Tokyo, Japan
R01CA125691 selected as an Exemplar of NCI-funded Translational Research (2008, 2009).
Golf Foundation
Patterson Trust
NE-SOT Best Poster (1997, 1999, 2007);
New Investigator AwardThe Donaghue Medical Research Foundation
New Investigator AwardAACP

We are about to launch the PI-initiated largest clinical trial at the UCONN Health Center in September. This study will develop personalized nutritional approaches to inhibit cancer risk factors in a population of at-risk patients.

I developed and direct an introductory survey course in Cancer Biology. This course is two credits and is offered every other year during the Spring semester. The course covers basic topics in cancer biology, from clinical aspects to molecular and genetic mechanisms and signaling to computational biology

Name & DescriptionCategoryRoleTypeScopeStart YearEnd Year
NIH, Cancer Chemoprevention Study Section (CPSS)Study SectionAd hoc reviewerExternalNational20212021
Current Pharmacology ReportsEditorial BoardEditorial Board MemberExternalInternational2020
Journal of Biochemistry and Molecular BiologyEditorial BoardEditorial Board MemberExternalInternational2020
Journal Cancer PreventionEditorial BoardMemberInternational2020
NCI, GI SPORE Program ReviewerProfessional/Scientific OrganizationReviewerExternalNational2019
NCI, Pre-cancer Genome Atlas (PCGA) Scientific Review PanelProfessional/Scientific OrganizationReviewerExternalNational20182018
American Institute Cancer Research, Grant Review PanelStudy SectionReviewerExternalNational2018
NCI, Pre-cancer Genome Atlas (PCGA) Think-Tank, NIHProfessional/Scientific OrganizationMemberExternalNational20172017
NCI PREVENT Cancer Program, Scientific Review PanelProfessional/Scientific OrganizationFull MemberExternalNational2017
NCI, GI SPORE Program ReviewerProfessional/Scientific OrganizationReviewerExternalNational20162016
NCI, Intramural Program ReviewerProfessional/Scientific OrganizationReviewerExternalNational20152015
NCI, Special Emphasis Panel, Cancer ChemopreventionProfessional/Scientific OrganizationMemberExternalNational20142014
American Institute Cancer Research, Grant Review PanelProfessional/Scientific OrganizationReviewerExternalNational20142021
Israel Cancer Research Foundation (ICRF)Study Sectiongrant reviewerOtherInternational20132013
COBRE NIH reviewStudy SectionreviewerOtherNational20132013
Cancer Prevention ResearchEditorial BoardEditorial Board MemberExternalInternational2012
NIH, Cancer Chemoprevention Study Section (CDP)Study SectionMemberExternalNational20102014
NIH Site Visit Team, Columbia University Cancer Center Advisory CommitteeMemberExternalState2008
Dartmouth-Hitchcock Cancer CenterProfessional/Scientific OrganizationMemberExternalLocal2008
NCI PO1 Advisory CommitteePanel memberExternalNational2008
Carcinogenesis Session Chair, AACR Professional/Scientific OrganizationChairExternalNational2008
NCI, Chemoprevention, Cancer GeneticsProfessional/Scientific OrganizationChairExternalNational2007
NIH, Cancer GeneticsProfessional/Scientific OrganizationMemberExternalNational20062007
CarcinogenesisEditorial BoardEditorial BoardExternalNational20062010
Colon Cancer Prevention Program, UCHC, Farmington, CTProfessional/Scientific OrganizationCo-DirectorUConn HealthUniversity2004
Molecular CarcinogenesisEditorial BoardEditorial BoardExternalNational20042020
NIH, Cancer Etiology Study Section (CE)Study SectionMemberExternalState20012006
Archives Pharmacal ResearchEditorial BoardEditorial BoardExternalNational2001
NIH Site Visit team, UT-MD Anderson Cancer CenterStudy SectionMemberExternalNational19971997

My laboratory has a longstanding interest in the molecular events that accompany early gastrointestinal neoplasia. We apply powerful and exquisitely sensitive cutting-edge technologies to understand the earliest cellular changes that precede cancer, including RNA-sequencing, computational biology, analysis of the microbiome, proteomics, epigenomics, metabolomics and basic aspects of cell biology (confocal imaging, imaging mass cytometry, organoid culture systems). We are also actively developing mouse genetic models to recapitulate human neoplasia, with a focus on colorectal cancer and inflammatory bowel disease. A major effort of our laboratory is to develop natural products that may be used to interrupt the processes of cancer initiation and progression. We are currently about to launch a large clinical trial to evaluate the benefits of plant-derived phytochemicals on cancer risk using pre and probiotics and personalized nutrition, a study that will involve extensive microbiome analysis in collaboration with investigators at the Jackson Laboratory for Genomic Medicine. This work will incorporate detailed bioinformatics and computational biology, as well as metabolomics and genomics analysis. In summary, we are deeply committed to developing novel strategies to prevent cancer, using natural products and personalized nutritional approaches. The work of our laboratory is highly collaborative, bridging the fields of cancer biology, stem cells, organoid culture systems, tumor immunology, epigenetics, metaboloimcs, genomics and the microbiome.

Early Onset Colorectal Cancer (Provocative Question, NCI)

Walnut-derived ellagitannins, microbiome and colon cancer risk markers (NCI)

Nutritional modulation of cancer chemotherapy (NCI)

Use of omega-3 fatty acids and NSAIDs for colon cancer prevention (NCI-PREVENT)

Accepting Lab Rotation Students: Summer 2022, Fall 2022, and Spring 2023

Lab Rotation Projects:

1. Understanding the molecular events associated with early neoplasia using laser capture microdissection and targeted expression profiling of inflammatory and immune-cell markers

2. Testing novel cancer prevention strategies using mouse genetic models of colorectal cancer

3. Defining the role of the microbiome and the related metabolome in cancer pathogenesis and prevention

4. Applying an array of NextGen and bioinformatics approaches to understanding the initiating events that accompany early precancerous changes in the colon, including detailed imaging mass cytometry (CyTOF) and targeted gene expression profiling

5. Testing the mechanisms by which natural products (e.g. whole foods, PUFAs) prevent cancer

6. Analyzing the epigenetic changes that are associated with cancer initiation and prevention using computational biology

7. Defining the role of the stromal microenvironment and proinflammatory cytokines in early stages of cancer

8. Understanding the role of activated fibroblasts as a contributing factor to the large increase in early onset colorectal cancer

9. Learn how to establish organoid culture systems to study the effects of pro-inflammatory cytokines on colon stem cells

Journal Articles

Book Chapters

  • Mo A, Jackson S, Devers T, Rosenberg DW, 2016 J Cell Biochemistry 117(12):2677-2781
  • Anthocyanins, Anthocyanin Derivatives, and Colorectal Cancer.
    Wang LS, Kuo CT, Peiffer D, Seguin C, Stoner K, Huang YW, Huang T, Salzman N, Liu Z, Rosenberg DW, Yang G, Yang W, Xiuli B, Carmella S, Hecht S, Stoner G, 2013 Anthocyanins in Health and Disease, Chapter 8
  • Chemical carcinogen models of colon cancer in rodents (invited review).
    Rosenberg DW, Giardina C, Tanaka T. Carcinogenesis, 30(2): 183:196
  • Complex roles of PGE2 in inflammation and cancer.
    Nakanishi M, Rosenberg DW. Seminars in Immunopathology, 35(2):123-37
  • Epidemiology of colonic aberrant crypt for foci: Review and analysis of existing studies.
    Stevens RG, Swede H, Rosenberg DW, 2007 "Cancer Letters", 252:171-183.
  • Global gene expression profiling: a complement to conventional histopathological analysis.
    Nambiar PR, Raja R, Rosenberg DW, 2005 "Veterinary Pathology" 42 (6):735-52
  • High throughput SNP/CGH approaches for the analysis of genomic instability in colorectal cancer.
    Brenner B, Rosenberg DW, 2010 Mutation Research, 693(1-2):46-52
  • mPGES-1 as a target for cancer suppression. (A comprehensive invited review) "Phospholipase A2 and lipid Mediators"
    Nakanishi M, Gokhale V, Meuillet EJ, Rosenberg DW, 2010 Biochimie 92(6):660-4
  • Murine models of ulcerative colitis.
    Flynn C, Levine J, Rosenberg DW, 2003 "Arch. Pharm. Res" 26(6)433-440
  • One-carbon metabolism and colorectal cancer: potential mechanisms of chemoprevention.
    Hanley M, Rosenberg DW, 2014 Current Pharmacology Reports, 1(3):197-205
  • Role of trace element interactions in metal excretion.
    Rosenberg DW, 1995 "Handbook on Metal-ligand Interactions in Biological Fluids" (G Berthon, ed.) Vol 2, Marcel-Dekker.
  • Roles of cPLA2-alpha and Arachidonic Acid in Cancer.
    Nakanishi M, Rosenberg DW, 2006 "Biochem Biophys Acta", 1761:1335-43.
  • Route of administration is a determinant of the tissue disposition and effects of TBTO on cytochrome P-450 dependent drug metabolism.
    Rosenberg DW, 1989 "Tin-Based Antitumor Drugs", NATO ASI Series, H73, M. Gielen (ed), Springer-Verlag, Berlin, 219-226.
  • Targeting notch signaling in colon cnacer stem cells.
    Miyamoto S, Rosenberg DW, 2011 Cancer Science 102(11):1938-42
  • The marked enhancement of heme degradation produced by organic derivatives of metals.
    Kappas A, Rosenberg DW, 1982 "Pathology-Anatomical and Clinical",XI Triennial World Congress of Pathology, E. Levy (ed.), Pergamon Press, Oxford, England, 531-534
  • Toxicological properties of organic derivatives of tin: Production of marked alterations of hepatic and extra-hepatic heme metabolism.
    Rosenberg DW, Kappas A, 1988 "Tin and Malignant Cell Growth", J J Zuckerman (ed.), CRC Press, Boca Raton, FL 126-136
  • Vitamin D resistance and colon cancer prevention.
    Giardina C, Brenner B, Madigan JP, Rosenberg DW, 2012 Carcinogenesis, 33(3):475-82

Conference Papers

  • Gene deletion of mPGES-1 results in a significant reduction in tumor stage and burden in the BBN mouse model of bladder cancer. Highly Rated Abstract, Top 2%
    Nakanishi M, Choudhary S, Hegde P, Pilbeam C, Rosenberg D, Taylor JA. 2010 Jan;51596-597


  • "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
    Stevens RG, Pretlow TP, Hurlstone DP, Giardina C, Rosenberg DW, 2008 Cancer Prevention Research 1(3):216
  • Colorectal Cancer
    Rosenberg DW, 2010 Mutation Research 693(1-2):1-2.



  • Multifaceted roles of PGE2 in inflammation and cancer.
    Nakanishi, Masako; Rosenberg, Daniel W Seminars in immunopathology 2013 Mar;35(2):123-37
  • Mouse models for the study of colon carcinogenesis.
    Rosenberg, Daniel W; Giardina, Charles; Tanaka, Takuji Carcinogenesis 2009 Feb;30(2):183-96
  • Roles of cPLA2alpha and arachidonic acid in cancer.
    Nakanishi, Masako; Rosenberg, Daniel W Biochimica et biophysica acta 2006 Nov;1761(11):1335-43
  • Global gene expression profiling: a complement to conventional histopathologic analysis of neoplasia.
    Nambiar, P R; Boutin, S R; Raja, R; Rosenberg, D W Veterinary pathology 2005 Nov;42(6):735-52
  • A flow cytometry-based reporter assay identifies macrolide antibiotics as nonsensemutation read-through agents.
    Caspi M, Firsow A, Rajkumar R, Skalka N, Moshkovitx I, Munitz A, Pasmanik-Chor M, Greif H, Megido D, Kariv R, Rosenberg DW, Rosin-Arbesfeld R, 2015 J Molecular Medicine 94(4):469-482
  • A highly sensitive fluorometric method for measuring ethoxycoumarin O-deethylase activity by reversed-phase high performance chromatography.
    Rosenberg DW, Roque H, Kappas A., 1990 Analytical Biochemistry, 191:354-358
  • A novel bioactive derivative of eicosapentaenoic acid (EPA) suppresses intestinal tumor development in Apc 14/wt mice.
    Nakanishi M, Hanley M, Igarashi Y, Mathias G, Sciavolino F, Rosenberg DW In preparation.
  • A phase IIa randomized, double-blind trial of erlotinib in inhibiting EGF receptor signaling in aberrant crypt foci of the colorectum.
    Gillen DL, Meyskens FL, Morgan T, Zell J, Caroll R, Benya R, Chen WP, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, gonzalez R, Rodriguez LM, Szabo E, Rosenberg DW, Lipkin SM, 2014 Cancer Prevention Research 8(3):222-30
  • A role for glucosylceramide synthase in resistance to oxapliplatin in colorectal cancer.
    Madigan JP, Cabot M, Obeid L, Hannun Y, Rosenberg DW In preparation.
  • Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy.
    Anderson JC, Swede H, Rustagi T, Protiva P, Pleau D, Brenner BM, Rajan TV, Heinen CD, Levine JB, Rosenberg DW, 2012 Cancer Causes Control, 23(2):355-61
  • Altered expression of Cyclin D1 and Cyclin-dependent Kinase 4 in azoxymethane-induced mouse colon tumorigenesis.
    Wang Q-S, Papanikolaou A, Sabourin CKL, Rosenberg DW, 1998 Carcinogenesis, 19:2001-2006
  • Anti-inflammatory effects of freeze-dried black raspberry powder in ulcerative colitis.
    Montrose DC, Horelik N, Madigan JP, Stoner GD, Wang LS, Bruno RS, Park HJ, Giardina C, Rosenberg DW, 2011 Carcinogenesis, 32(3):343-50
  • Association of dietary fat and risk of proximal colon neoplasia in a population-based study.
    Mo A, Wu R, Grady J, Hanley M, Swede H, Devers T, Hartman T, Rosenberg DW Under review.
  • Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility.
    Papanikolaou A, Wang Q-S, Delker DA, Rosenberg, DW 1998 Cancer Letlter, 130:29-34
  • CD13 is dispensable for normal hematopoiesis and myeloid cell functions in the mouse.
    Winnicka B, O'Conor CA, Schacke W, Vernier K, Grant CL, Fenteany FH, Pereira FE, Liang B, Kaur A, Zhao R, Montrose DC, Rosenberg DW, Aguila HL, Shapiro LH, 2010 J Leukocyte Biologym 88(2):347-59
  • Characterization of heme oxygenase in thesmall intestinal epithelium.
    Rosenberg, DW, Kappas, A., 1989 Archives of Biochemistry and Biophysics, 274:471-480
  • Chlorogenic acid differentially alters hepatic and small intestinal thiol redox status without protecting against AOM-induced colon carcinogenesis in mice.
    Park HJ, Davis SR, Liang HY, Rosenberg DW, Bruno RS, 2010 Nutrition and Cancer, 72(3):362-370
  • Chromoendoscopy coupled with DNA Mass Spectrometry Profiling Identifies Somatic mutations in microdissected human proximal aberrant crypt foci.
    Drew DA, Devers TJ, O'Brien MJ, Horelik NA, Levine J, Rosenberg DW, 2014 Molecular Cancer Research, 12(6):823-9 (article featured on front cover)
  • Colorectal polyp prevention by daily aspirin use in abrogated among active smokers.
    Drew DA, Goh G, Mo A, Grady JJ, Forouhar F, Egan G, Swede H, Rosenberg DW, Stevens RG, Devers, TJ, 2016 Cancer Causes Control
  • Comparative metabolic response to the colon carcinogen, 1,2-dimethylhydrazine, in inbred mice.
    Delker DA, Bammer T, Eaton D, Rosenberg DW, 1996 Drug Metabolism and Disposition, 24:408-413
  • Comparative pharmacokinetics of cobalt chloride and cobalt protoporphyrin
    Rosenberg DW., 1993 DrugMetabolism and Disposition
  • CPLA2 is protective against COX inhibitor-induced intestinal damage.
    Montrose DC, Kadaveru K, Ilsley JN, Root SH, Rajan TV, Ramesh M, Nichols FC, Liang BD, Sonin D, Hand AR, Zarini S, Murphy RC, Belinsky GS, Nakanishi M, Rosenberg DW, 2010 Toxicological Sciences, 117(1):122-32
  • Cyclooxygenase-1 and 2 play contrasting roles in Listeria stimulated immunity.
    Theisen E, McDougal E, Nakanishi M, Rosenberg DW, Sauer JD Under review.
  • Cytochemical localization of a cytochrome P450 isoform, cyp2e-1, within mouse colon.
    Parke B, Ying L, Averill D., Jr., Jackman MI, Rosenberg, DW, 1995 Pharmacology 50:339-347
  • Definihg the role of cancer associated fibroblasts in neoplastic progression of colorectal cancer.
    Bortniker E, Huang H, Rosenberg DW In preparation
  • Diallyl sulfide enchances azoxymethane-induced preneoplasia in Fischer 344 rat colon.
    Delker DA, Papanikolaou A, Suhr YJ, Rosenberg DW, 2000 Chemico-Biological Interactions 124:149-160
  • Dietary black raspberries modulate DNA methylation in dextran sodium sulfate(DSS) induced ulcerative colitis.
    Wang LS, Kuo CT, SToner K, Yearsley M, Oshima K, Yu J, Huang TH, Rosenberg DW, Peiffer D, Stoner GD, Huang YW,2013 Carcinogenesis, 34(12):2842-50
  • Dietary methyl donor restriction suppresses intestinal adenoma development.
    Hanley M, Kadaveru K, Perret C, Giardina C, Rosenberg DW, 2016 Cancer Prevention Research 9(10):812-820
  • Dietary modulation of cytochrome P450 in the small intestinal epithelium.
    Rosenberg, DW 1991 Pharmacology, 43:36-46
  • Direct in vitro effects of bis(tri-n-butyltin) oxide on hepatic cytochrome P-450.
    Rosenberg, DW,Drummond, GS., 1983 Biochemical Pharmacology 32:3823-3829
  • Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate.
    Mounier CM, Wendum DE, Greenspan E, Feljou JF, Rosenberg DW and Lambeau G, 2008 BR. J. Cancer, 98(3):587-95
  • Effects of walnut consumption on colon carcinogenesis and microbial community structure.
    Nakanishi M, Chen Y, Quendro V, Miyamoto S, Weinstock E, Weinstock GM, Rosenberg DW,2016 Cancer Prevention Research, 9(8):692-703
  • Epigenetic regulation of VDR expression in Apc-mutant mice, human colon cnacers and adenomas.
    Giardina C, Nakanishi M, Khan A, Kuratnik A, Xu W, Brenner B, Rosenberg DW, 2015 Cancer Prevention Research 8(5):387-99
  • Epithelial-stromal interactions are altered at the earliest states of colon cancer development.
    Mo A, Jackson S, Varma K, Carpino A, Giardina G, Devers TJ, Rosenberg DW, 2016 Molecular Cancer Research, 14(9):795-804, selected for the Highlights Section
  • Expression analysis of the group IIA secretory phospholipase A2 in mice with differential susceptibility to azoxymethane-induced colon tumorigenesis.
    Papanikolaou A, Wang Q-S, Rosenberg DW, 2000 Carcionogenesis 21-!33-138
  • Factors affecting lead concentrations in drinking water: Solder and Sediment.
    Stimpfel T, Volin C., Rosenberg DW, Gershey EL., 1991 Applied Occupational and Environmental Hygiene, 6:44-48
  • Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis and alters anti-tumor immunity.
    Nakanishi M, Montrose DC, Vella AT, Menoret A, Rosenberg DW, 2011 Cancer Prevention Research, 4(8):1198-2208
  • Genetic deletion of MPGES-1 suppresses intestinal tumorigenesis.
    Nakanishi M, MontroseDS, Clark P, Namblar PR, Belinsky GS, Claffey KP, Xu D, Rosenberg DW, 2008 Cancer Research, 68(9):3251-9 (selected for fron cover).
  • Genetic inactivation of mPGES-1 reduces inflammation and carcinogenesis in the BBN bladder cancer model.
    Nakanishi M, Choudhary S, Choudhary D, Hegde P, Pilbeam C, Rosenberg DW, Taylor JA In preparation.
  • Genome-wide changes distinguish sulindac responsive tumors in the colon.
    Miyamoto S, Hanley M, Rosenberg DW In preparation.
  • Genome-wide DNA methylation profiling reveals cancer-associated changes within early colonic neoplasia. (Epub)
    Hanley MP, Hahn MA, Li AX, Wu X, Lin J, Wang J, Choi AH, Ouyang Z, Fong Y, Pfeifer GP, Devers TJ, Rosenberg DW, 2017 Oncogene
  • HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on WNT and vitamin D signaling.
    Godman CA, Joshi R, Tierney BR, Greenspan E, Rasmussen TP, Wang HW, Shin DC, Rosenberg DW, Giradina C, 2008 Cancer Giol Ther 7(10):1570-80
  • HDAC3 over-expression and colon cancer cell proliferation and differentiation.
    Spurling CC, Godman, CA, Noonan EJ, Rasmussen TP, Rosenberg DW, Giardina C, 2008 Molecular Carcinogenesis, 47(2):137-47
  • Ibuprofen inhibits activation of nuclear B-catenin in human colon adenomas and induces the phosphorylation of GSK-3B.
    Greenspan ERJ, Madigan JP, Boardman LA, Rosenberg DW, 2011 Cancer Prevention Research, 4(1):161-71.
  • Identifying novel targets for resveratrol in human colorectal cancer cells.
    Menoret A, Drew D, Nakanishi M, Vella AT, Rosenberg DW, 2012 Molecular Carcinogenesis, (Epub, Dec 2012)
  • In vitro cytoxicity with the the fish hepatoma celel line, PLHC-1(Poeciliopsis Lucida).
    Babich, H, Rosenberg, DW, Borenfreund, E., 1991 Ecotoxicology and Environmental Safety: 21:327-336
  • In vitro response of the brown bullhead catfish cell line, BB, to aquatic pollutants.
    Martin-Alguacil N, Babich H, Rosenberg, DW, Borenfreund, E., 1991 Archives Environmental Contamination and Toxicology
  • In vitro response of the brown bullhead catfish cell line, BB, to aquatic pollutants.
    Martin-Alguacil N, Babich H, Rosenberg, DW, Borenfreund, E., 1991 Archives Environmental Contamination and Toxicology
  • In vivo intestinalmetabolish of 7-ethoxycoumarin in the rat: Production and distribution of phase I and phase II metabolites in the isolated, perfused intestinal loop.
    Albers R, Rosenberg DW., 1991 Toxicology and Applied Pharmacology, 109:507-513
  • Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice.
    Chang HH, Moro A, Takakura K, Su H, Mo A, Nakanishi M, Waldron R, French S, Dawson D, Hines O, Li G, Liang V, Sinnett-Smith, J, Pandol S, Lugea A, Gukovskaya A, Duff M, Rosenberg DW, Rozengurt E, Guido E, PLOS One (in revision)
  • Increased frequency of serrated aberrant crypt foci among long-term smokers.
    Anderson JC, Pleau D, Rajan TV, Protiva P, Swede S, Brenner B, Heinen C, Lambrecht RW, Rosaenberg DW, 2010 American Journal Gastroenterology, 105(7):1648-54
  • Induction if heme oxygenase in the small intestinal epithelium: A response to oral cadium exposure.
    Rosenberg DW, Kappas A., 1991 Toxicology, 67:199-210
  • Induction of aberrant crypts in murine colon with varying sensitivity to colon Carcinogensis.
    Rosenberb DW, Liu Y, 1995 Cancer Letter, 92:209-214
  • Induction of cyp2e-1 protein inmouse colon.
    Mankowski D, Rosenberg DW, 1994 Carcinogenesis, 15:73-78
  • Inhibition of intestinal heme oxygenase activity and increased iron production in the bile of rats by synthetic metalloporphyrins.
    Drummond GS, Rosengerg DW, Kappas A., 1992 Gastroenterology, 102:1170-1175
  • Initial levels of azoxymethane induced DNA methyl adduct are not predictiveof tumor susceptibility in inbred mice.
    Papanikolaou A, Shank RL, Delker D, Povey A, Cooper DP, Rosenberg DW, 1998 Toxicology and Applied Pharmacology150:196-203
  • Intestinal lineage commitment of embryonic stem cells.
    Cao L, Gibson JD, Miyamoto S, Sail V, Verma R, Rosenberg DW, Nelson CE, Giardina C, 2011 Differentiation, 81(1):1-10
  • Loss of the polycomb mark from bivalent promoters leads to activation of cancer-promoting genes in colorectal tumors
    Hahn MD, Li Ax, Wu X, Yang R, Drew DA, Rosenberg DW, Pfeifer GP, 2014 Cancer Research, 74(13):3617-29
  • Metabolomics underlie colon tumor protection by methyl donor restriction.
    Hanley M, Kadaveru K, Rosenberg DW In preparation.
  • Metal induction of haem oxygenase without concurrent degradation of cytochrome P-450. Protective effects of SKF 525A on the haem protein.
    Drummond,GS, Rosenberg, DW, Kappas, A., 1982 Biochemical Journal, 202:59-66
  • Moderate dietary methyl donor depletion suppresses intestinal tumorigenesis and inflammatory response markers in Apc Min/+ mice.
    Kadaveru K, Protiva P, Greenspan E, Nakanishi N, and Rosenberg DW, 2012 Cancer Prevention Research, 5(7):911-20
  • Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+mice.
    Greenspan EJ, Nichols FC, Rosenberg DW, 2010 Cancer Prevention Research 3(9):1187-97
  • Nanoproteomic analysis of extracellular receptor kinase-1/2 post-translational activation in microdissected human hyperplastic colon lesions.
    Drew D, Devers T, Horelik N, Yang S, O'Brien M, Wu R, Rosenberg DW, 2013 Proteomics, 13(9):1428-36
  • Non-cell autonomous effects of targeting inducible PGE2 synthesis during inflammation associated colon cancer.
    Nakanishi M, Miyamoto S, Meuillet EJ, Rosenberg DW, 2015 Carcinogenesis 36(4):478-86
  • Non-homogeneous marking of distal colonicmucosa using Dolichos biflorus lectin.
    Rosenberg, DW 1995 Cancer Letters, 98:33-37
  • Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability.
    Swede H, Rohan T, Yu H, Stevens R, Brokaw J, Levine J, Anderson J, Pleau D, Rosenberg DW, 2009 Cancer Causes and Control, 20(5):653-61
  • Overexpression of Apolipoprotein C11 causes hypertriglyceridemia in transgenic mice
    Schacter NS, Hayek T, Leff T, Smith JD, Rosenberg DW, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL., 1994 Journal of Clinical Investigation93:1683-1690
  • Oxidative metabolism of estrogens in rat intestinal mitochondria.
    Michnovicz J, Rosenberg DW., 1992 Biochemical Pharmacology, 43:1847-1852
  • Pharmacological inhibitionof Mdm2 triggers growth arrest and stabilizes DNA breaks in vitro and in vivo.
    Rigatti MJ, Verma R, Belinsky GS, Rosenberg DW, Giardina C, 2011 Molecular Carcinogenesis, 51(5):363-78
  • Planar spindle orientation and asymmetric cytokinesis in the mouse small intestine.
    Fleming ES, Zajac M, Moschenross DM, Montrose D, Rosenberg DW, Cowan AE, Tirnauer JS, 2007 J Histochemistry Cytochemistry, 55(11):1173-80
  • Preliminary analysis of azoxymethane-induced colontumorigenesis in mouise aggregation chimeras.
    Wang Q-S, Goldsby J, Walsh A, Bolt A, Rosenberg DW, 1999 Carcinogenesis, 20:691-697
  • Prolonged induction ofhepatic heme oxygenase and decreases in cytochrome P-450 content by organotin compounds. 1980
    Drummond, GS, Corish HH,Kappas A. Biochemical Journal,190:465-468
  • Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection.
    Chen JH, Perry C, Tsui YC, Staron Mm, Parish IA, Dominguez CZ, Rosenberg DW, Kaech SM, 2015 Nature Medicine 21(4):327-34
  • Proximal aberrant crypt foci are associated with synchronous neoplasia and primed for neoplastic development.
    Drew D, Mo A, Grady J, Stevens R, Brenner B, Anderson J, Levine J, O'Brien M, Devers T, Rosenberg DW (Under review)
  • Quantitative assessment of azoxymethane-induced aberrant crypt foci in inbred mice.
    Delker DA, Wang Q-S, Papanikolaou A, Whiteley HE, Rosenberg DW, 1999 Experimental and Molecular Pathology, 65:141-149
  • Regulation of cytochrome P450 in cultured human colonic epithelial cells (CaCo-2)
    Rosenberg DW, Leff T., 1993 Archives of Biochemistry and Biophysics 300:186-192
  • Response of cultured human cells to polycyclicaromatic hydrocarbons: establishing an in vitro alternative to the Draize rabbit skin irritancy test.
    Babich H, Martin-Alguacil N,Rosenberg DW, Borenfreund, E., 1991 Ecotoxicology and Environmental Safety 19:65-71
  • Rodent strain and species differences in the bioactivation of the colon carcinogen methylazoxymethanol by alcohol dehydrogenase.
    Delker DA, KcKnight S, Rosenberg DW, 1998 Toxicological Sciences, 45:66-71
  • Route of administration as a determinant of organotin effects on hepatic and intestinal cytochrome P-450 content and function.
    Rosenberg, DW, Kappas, A., 1989 Main Group Metal Chemistry 12(1), 17-29
  • Sex differences in associations between psychosocial factors and aberrant crypt foci among patients at risk for colon cancer.
    O'Leary KE, Cruess DG, Pleau D, Swede H, Anderson J, Rosenberg DW, 2011 Gender Medicine, 9=8(3):165-71
  • Strain-specific homeostatic responses during early stages of azoxymethane-induced colon tumorigenesis in mice.
    Guda K, Marino JN, Jung Y, Crary K, Dong M, Rosenberg DW, 2007 Int J Oncology 31(4):837-42
  • Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.
    Morad SA, Madigan JP, Levin JC, Abdelmageed N, Karimi R, Rosenberg DW, Kester M, Shanmugavelandy SS, Cabot MC, 2013 Biochemical Pharmacology, 85(8):1057-65
  • Targeting colon cancer stem cells with Notch inhibitors.
    Miyamoto S, Rosenberg DW, 2013 Carcinogenesis, 34(10:2415-23
  • The actions of orally administered organotin compounds on heme metabolism and cytochrome P-450 content and function in intestinal epithelium.
    Rosenberg, DW, Kappas, A., 1989 Biochemical Pharmacology, 38(7), 1155-1161
  • The altered induction response of hepatic cytochrome P-450 to phenobarbital, 3-methylcholanthrene, and B-naphthoflavone in organotin-treated animals.
    Rosenberg, DW, Sardana, MK, Kappas, A., 1985 Biochemical Pharmacology, 34:997-1006
  • The comparative abilities of inorganic cobolt and cobalt protoporphyrin to affect copper metabolism and produce a prolonged elevation in plasma ceruloplasmin.
    Rosenberg D, Kappas A,. 1995 Pharmacology 50:201-208
  • The effectsof tin-porphyrins on developmental changes in hapatic cytochrome P450 content, selected cytochrome P450-dependent drup metabolizing enzyme activities and brain glutathione levelsin the newborn rat.
    Drummond, GS, Rosenberg, DW, Kihlstron-Johanson, AC,Kappas, A., 1989 Pharmacology, 39:273-284
  • The In vitro and in vivo inhibition of intestinal heme oxygenase by tin-protoporphyrin.
    Rosenberg, DW, Drummond, GS, Kappas, A., 1989 Pharmacology, 39:224229
  • The influence of organometals on heme metabolism - in vivo and in vitro studies with organotins.
    Rosenberg, DW, Drummond, GS, Kappas, A., 1982 Molecular Pharmacology 21:150-158
  • The potent induction of intestinal heme oxygenase by the organotin compound, bis(tri-n-butyltin) oxide.
    Rosenberg, DW, Anderson, KE, Kappas, A., 1984 Biochemical Biophysical Research Communications, 119:1022-1027.
  • The role of PGE2 in intestinal inflammation and tumorigenesis.
    Montrose DC, Nakanishi M, Vella A, Rosenberg, DW 2014 Prostaglandins and Other Lipid Mediators, 116-117C:26-36
  • The short chain fatty acid butyrate induces promoter demethylation and reactivation of RARbeta2 in colon cancer cells.
    Spurling CC, Suhl JA, Boucher N, Nelson CE, Rosenberg DW, Giardina C, 2008 Nutrition and Cancer, 60-(5):692-702
  • Thyroid hormone regulation of cytochrome P450 is independent of heme oxygenase induction.
    Rosenberg DW, Drummond GS, Smith TJ, 1995 Pharmacology, 51:254-262
  • Tissue specific inductin of the carcinogen inducible cytochrome P450 isoform, P4501A1in colonic epithelium.
    Rosenberg DW, 1991 Archivesof Biochemistry and Biophysics, 284:223-226
  • Trace metal interactions in vivo: Inorganic cobalt enhances urinary copper excretion without producing an associated zincuresis in rats.
    Rosenberg, DW, Kappas, A., 1989 Journal of Nutrition, 119:1259-1268
  • Transgenicexpression of Cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression.
    AlSalihi MA, Pearman AT, Doan T, Reichert EC, Rosenberg DW, Prescott SM, Stafforini DM Topham MK, 2009 Cancer Letters, 273(2):225-35
  • Utilizing endoscopic technology to reveal real-time proteomic alterations in response to chemoprevention.
    Nakanishi M, Menoret, Belinsky GS, Giardina C, Godman CA, Vella AT, and Rosenberg DW, 2007 Proteomics Clin. Appl. 1:1660-1666 (selected as the picture of the monthin this issue)

Short Surveys

Title or AbstractTypeSponsor/EventDate/YearLocation
3rd Meeting of the International Society of Precision Cancer MedicineLecture2019Seoul, South Korea
Seoul National University School of BioengineeringLecture2019Seoul, South Korea
Cha Bio ComplexLectureCHA University2019Seongnam, South Korea
Scientific Advisory CommitteeLectureCalifornia Walnut Board and Commission2019San Diego, CA
University of Illinois Cancer CenterLecture2019Champaign-Urbana, Ill
Grand Rounds, School of MedicineLectureUCONN Health Center2019Farmington, CT
Department of Nutritional SciencesTalkUniversity of Connecticut2019Storrs, CT
Israel's Role in Cancer ResearchLectureICRF2019West Hartford, CT
FoodFluence 2018Lecture2018Lisbon, Portugal
Albert Einstein College of MedicineLecture2018Bronx, NY
Digestive Disease WeekLecture2017Chicago, Illinois
Pre-cancer Atlas (PCA) Think Tank MeetingLectureNational Cancer Institute2017Bethesda, MD
Scientific Advisory CommitteeLectureCalifornia Walnut Board and Commission2017Carmel, CA
Ventana Distinguished Research Seminar SeriesLecture2017Tuscan, AZ
ThermoFisher Genomics WorkshopLectureSociety for the Immunotherapy of Cancer2017Washington, DC
International Cancer Microbiome Consortium (ICMC)Lecture2017London, United Kingdom
University of South Carolina School of MedicineLecture2016Columbia, SC
University of Maryland School of MedicineLecture2016Baltimore, MD
CURE: Digestive Diseases Research CenterLectureUCLA2016Los Angeles, CA
American Association for Cancer ResearchLecture2016New Orleans, LA
SAB meetingLectureCalifornia Walnut Commission2016Maui, HI
"Cancer chemoprevention with botanicals, herbal medicines, and phytochemicals"LectureRutgers University2016New Brunswick, NJ
Department of NutritionLecturePurdue University2016Lafayette, IN
SUNY Cancer CenterLectureSUNY2015Stony Brook, NY
Seoul National UniversityLecture2015Seoul, South Korea
Seoul National University College of MedicineLecture2015Seoul, South Korea
Asian Congress of NutritionLecture2015Yokohama, Japan
Japanese National Cancer CenterLecture2015Tokyo, Japan
Gifu Municipal HospitalLecture2015
Van Andel InstituteLecture2015Grand Rapids, Michigan
SNUCRI Cancer SymposiumLectureSNUCRI2014Mokpo, Korea
International Symposium on Microgenomics 2014Lecture2014Paris,France
Tel Aviv University Sackler School of MedicineLectureTel Aviv University2014Israel
Ichilov Hospital, Department of GastroenterologyLectureIchilov Hospital2014Tel Aviv, Israel
CSSI Science DayLectureNational Cancer Institute2014Bethesda, MD
SUNY Cancer CenterLectureSUNY2014Stony Brook, NY
Microgenomics Thought Leader SummitLectureThermo-Fischer2014South San Francisco, CA
Genomics Application Workshop PresentationLectureAmerican Society Human Genetics2014San Diego, CA
American Institute of Cancer Research Annual MeetingLectureAmerican Institute of Cancer Research2014Washington, DC
Nutritional Targets for Colon Cancer PreventionLectureNutrition Graduate Seminar Series2014Texas A&M
Obesity Research SymposiumLectureMarshall University School of Medicine2013Huntington, West VA
Proximal human aberrant crypt foci as surrogate markers of colorectal cancer riskPoster2013Wilmington, NC
Obesity as a risk factor for colorectal cancerPlenary LectureMarshall University Childhood Obesity Conference2013Huntington, West Virginia
American Association of Clinical Endocrinology (AACE)LectureAACE2012New York, New York
Kansas State UniversityLectureCOBRE Program2012Manhattan, KS
Seoul National University Cancer Research Institute SymposiumLecture2012Seoul, Korea
Center for Tumor MicroenvironmentLectureCollege of Pharmacy2012Seoul, Korea
California Walnut Commission Scientific Advisory Board MeetingLectureCWC2012Honolulu, Hawaii
University of Arizona Cancer CenterLecture2011Tucson, AZ
University of Tel AvivLecture2011Tel Aviv, Israel
Ichilov HospitalLecture2011Tel Aviv, Israel
New York Medical CollegeLecture2011Valhalla, NY
Berry Health Benefits SymposiumLecture2011West Lake Village, CA
Department of Chemical BiologyLectureRutgers University2011New Brunswick, NJ
Molecular and Cell Biology, University of Connecticut, Storrs, CTLecture2010
University of New Mexico Cancer CenterLecture2010Albuquerque, NM
John Wayne Cancer InstituteLecture2010Santa Monica, CA
University of Kansas School of MedicineLectureCancer Center2010Kansas City, KA
Fox-Chase Cancer CenterLecture2010Philadelphia, PA
The International Cancer Research Symposium 2010: Defining and Translating Science Behind the DiseaseLecture2010Thiruvananthapuram, India
Lombardi Cancer CenterLectureGeorgetown University2009Washington, DC
Arizona Comprehensive Cancer CenterLectureUniversity of Arizona2009Tuscan, AZ
Sylvester Cancer CenterLectureUniversity of Miami2009Miami, FL
4th International Conference on Phospholipase A2 and Lipid MediatorsLecture2009Tokyo, Japan
Gifu UniversityLectureInstitute for Cancer Research2009Gifu, Japan
Lipid Signaling Pathways in CancerLectureFASEB Summer Research Conference2009Carefree, AZ
Weill-Cornell Medical CollegeLectureDepartment of Surgery2009New York, NY
Invited Plenary Lecture, Eighth Annual AARC Conference on Frontiers in Cancer Prevention ResearchLecture2009Houston, TX
UCHC, Recent Advances in Internal Medicine, 'Molecular models for chemoprevention in the future'Lecture2008
UCHC, Recent Advances in Internal Medicine, 'Molecular models for chemoprevention in the future'Lecture2008
UCHC, Recent Advances in Internal Medicine, 'Molecular models for chemoprevention in the future'Lecture2008
UCHC, Recent Advances in Internal Medicine, 'Molecular models for chemoprevention in the future'Lecture2008
American Association for Cancer Research (two oral presentations)Lecture2008San Diego, CA
Louisiana State University Cancer CenterLecture2008New Orleans, LA
American Association for Cancer ResearchLectureSession Chairman2008San Diego, CA
National Cancer Center Research InstituteLecture2008Tokyo, Japan
Tokyo Metropolitan Medical InstituteLecture2008Tokyo, Japan
Kyoto University School of MedicineLecture2008Kyoto, Japan
Kanazawa Medical UniversityLecture2008Kanazawa, Japan
NCI TranslatesLecture2008Washington, DC
Lombardi Cancer CenterLectureGeorgetown University2008Washington, DC
University of PittsburghLecture2008Pittsburgh, PA
University of ColoradoLecture2008Denver, CO
Oklahoma Medical Research FoundationLecture2007Oklahoma City, OK
Burnham InstituteLecture2007LaJolla, CA
FASEB Summer Conference on Bioactive Lipid MediatorsLectureFASEB2007Indian Wells, CA
Bioactive Lipids in Cancer, Inflammation and Related DiseasesLecture2007Montreal, Canada
International Symposium on Genetic, Pharmacologic and Nutritional Modulations of CarcinogenesisLecture2007Seoul, Korea
9th International Conference on Mechanisms of Anti-mutagenesis and Anti-carcinogenesisLecture2007Jeju Island, Korea
Department of Cell BiologyLectureAlbert Einstein College of Medicine of Yeshiva University2006Bronx, NY
Pathology Lecture SeriesLectureWayne State University School of Medicine2006Detroit, MI
Gene Expression in Tumors - Discovery and DiagnosticsLectureLongwood Medical Center2006Boston, MA
City of HopeLectureDivision of Biology2005Duarte, CA
American Association for Cancer ResearchLecture2005Anaheim, CA
STADY ConferenceLectureTel Aviv University2005Israel
STADY ConferenceLectureTel Aviv University2005Israel
Experts meeting on Toxicogenomics and PharmacogenomicsLectureBoeringher-Ingelheim2004New York, NY
Arcturus EngineeringLecture2004Palo Alto, CA
Phospholipase ConferenceLectureInternational PAF2004Berlin, Germany
Phospholipase ConferenceLectureInternational PAF2004Berlin, Germany
Cambridge Health Tech Institute 2nd Annual LCM SymposiumLectureCambrige Health Tech Institute2004Boston, MA
IHC Meeting, presentation and workshop on LCMLectureIHC2004San Diego, CA
ACF pathobiology and its implications for biomarker development related to colorectal cancer risk and preventive responseLectureNCI2004Rockville, MD
Department of Rheumatology, Toxicogenomics of MethotrexateLecture2003
Department of Rheumatology, Toxicogenomics of MethotrexateLecture2003
UCLALectureHarbor Medical Center2003Torrance, CA
University of Arizona Cancer CenterLecture2003Tucson, AZ
Genomic and Proteomic Sample Preparation Short Course (Co-Chair)Lecture2003Boston, MA
Liver Hepatoxicity Mini-SymposiumLectureBoeringher-Ingelheim2003Ridgefield, CT
Department of Pharmaceutical SciencesLectureUniversity of Pittsburgh2003Pittsburgh, PA
University of IllinoisLectureSchool of Veterinary Sciences2003Champagne-Urbana, IL
Environmental Protection AgencyLecture2003Research Triangle Park, NC
Huntsman Cancer InstituteLecture2002Salt Lake City, UT
University of Massachusetts School of MedicineLecture2002Worcester, MA
Symposium on the Effects of Oxidant Balance on Breast and Colon CancerLecture2002New York, NY
Keynote Lecture, 2nd Australian Microarray ConferenceLecture2002Courant Cove, Australia
Molecular Profiling of Normal Development and Pathology in Tissues: Integrating Laser Microdissection and MicroanalysisLectureNIH2002Bethesda, MD
Department of Environmental MedicineLectureNew York University2002Tuxedo, NY
Enabling Molecular Profiling with Cellular ResolutionLectureCambridge Health Tech Institute2002San Diego, CA
M.D. Anderson Cancer CenterLectureUniversity of Texas2001Science Park, TX
Department of GeneticsLecture2001Farmington, CT
Department of GastroenterologyLecture2001
Department of Pathology, UCHC, Farmington, CTLecture2001
American Association of Cancer ResearchLectureMini-symposium2001New Orleans, LA
Department of Human GeneticsLectureUMDNJ at Rutgers University2000Piscataway, NJ
Department of PathologyLectureYale University School of Medicine2000New Haven, CT
National Institute of Environmental Health SciencesLecture1999Research Triangle Park, NC
Pathobiology Seminar SeriesLectureDepartment of Medical Oncology, Brown University1999Providence, RI
Department of Pharmacology and ToxicologyLectureMedical College of Virginia1999Richmond, VA
University of Puerto RicoLectureDepartment of Biochemistry1999San Juan, PR
Signal Transduction Seminar SeriesLectureParke-David Pharmaceutical Research1998Ann Arbor, MI
Starr Center for Human Genetics, HHMILectureRockefeller University1998NY, NY
1st Annual Meeting on Rodent Models in Modern Risk AssessmentLectureThe Jackson Laboratory1998Bar Harbor, ME